BioSpace News Archive

First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COVTM(1) increased 20%

Pfizer Inc. and BioNTech SE announced the signing of a Memorandum of Understanding with the International Olympic Committee to donate doses of the companies’ COVID-19 Vaccine to help vaccinate athletes, and their delegations, participating in the Olympic and Paralympic Games Tokyo 2020, which are scheduled to begin on July 23, 2021.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended March 31, 2021, and provided an update on the Company’s business operations and clinical development programs.

Madrigal Pharmaceuticals, Inc. announced its first quarter 2021 financial results and highlights.

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that Peter J. Mariani, executive vice president and chief financial officer will present at the Canaccord Genuity Musculoskeletal Conference.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it will host a live conference call and audio webcast on Thursday, May 13, 2021 at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2021, and to provide a corporate update.

CV Sciences, Inc., a preeminent supplier and manufacturer of hemp cannabidiol products, announced that it will release financial results for the first quarter ended March 31, 2021, after the stock market closes on Thursday, May 13, 2021.

First-Time Data for KEYTRUDA® (pembrolizumab) in Early-Stage Kidney Cancer and for LYNPARZA® (olaparib) in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session

Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the BofA Securities 2021 Healthcare Conference.

Worldwide Ocaliva® net sales of $81.7M, representing 12% growth over the prior year quarter Company narrows 2021 financial guidance; now expects worldwide Ocaliva net sales guidance of $325 million to $340 million and reiterates Non-GAAP adjusted operating expense guidance of $380 to $410 million Process between Intercept and FDA remains ongoing regarding updates to the Ocaliva U.S.